-
Article
Open AccessTreatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines
Patients with HBeAg-negative chronic hepatitis B may experience an immune response after stop** nucleos(t)ide analogue (NA)therapy, which may potentially trigger HBsAg loss or off-therapy sustained viral con...
-
Article
Open AccessA new approach to prevent, diagnose, and treat hepatitis B in Africa
There are 82 million people living with hepatitis B (PLWHB) in the World Health Organization Africa region, where it is the main cause of liver disease. Effective vaccines have been available for over 40 years...
-
Article
Open AccessFive-year results of a treatment program for chronic hepatitis B in Ethiopia
In sub-Saharan Africa, less than 1% of treatment-eligible chronic hepatitis B (CHB) patients receive antiviral therapy. Experiences from local CHB programs are needed to inform treatment guidelines and policie...
-
Article
Open AccessInforming a target product profile for rapid tests to identify HBV-infected pregnant women with high viral loads: a discrete choice experiment with African healthcare workers
Elimination of mother-to-child transmission of hepatitis B virus (HBV) requires infant immunoprophylaxis and antiviral prophylaxis for pregnant women with high viral loads. Since real-time polymerase chain rea...
-
Article
Open AccessEfficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants.
-
Article
Open AccessSystematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa
In sub-Saharan Africa, simple biomarkers of liver fibrosis are needed to scale-up hepatitis B treatment. We conducted an individual participant data meta-analysis of 3,548 chronic hepatitis B patients living i...
-
Article
Open AccessPersistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9
The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment t...
-
Article
Open AccessPredictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study
Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we a...
-
Article
Open AccessTreatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia
The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) ...
-
Article
Open AccessUnexplained chronic liver disease in Ethiopia: a cross-sectional study
Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence o...
-
Article
Open AccessRisk factors for coronary artery disease in patients undergoing elective coronary angiography in Jordan
Unhealthy lifestyle factors such as smoking, obesity, inactivity and type 2 diabetes are endemic in the Middle East. The public health consequences might be detrimental; however, local studies on risk factors ...
-
Article
Open AccessEarly experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa
Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia.
-
Article
Open AccessAntiretroviral treatment reverses HIV-associated anemia in rural Tanzania
HIV-associated anemia is common and associated with poor prognosis. However, its response to antiretroviral treatment (ART) in rural Africa is poorly understood.
-
Article
Open AccessVirological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania
Virological response to antiretroviral treatment (ART) in rural Africa is poorly described. We examined virological efficacy and emergence of drug resistance in adults receiving first-line ART for up to 4 year...
-
Article
Open AccessPredictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania
Studies of antiretroviral therapy (ART) programs in Africa have shown high initial mortality. Factors contributing to this high mortality are poorly described. The aim of the present study was to assess mortal...
